{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 457123161
| image =  
<!-- Monoclonal antibody data -->
| type = mab
| mab_type = mab
| source = zu
| target = [[FR-alpha]]
<!-- Clinical data -->
| tradename =  
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled -->
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status =  
| routes_of_administration =  
<!-- Pharmacokinetic data -->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  
<!-- Identifiers -->
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = none
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 896723-44-7
| ATC_prefix = none
| ATC_suffix =  
| PubChem =  
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 2O09BG0OWA
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D09343
<!-- Chemical data -->
| C=6466 | H=9928 | N=1716 | O=2020 | S=42
| molecular_weight = 145.4 kg/mol
}}
'''Farletuzumab''' ('''MORAb-003''') is a [[monoclonal antibodies|monoclonal antibody]]<ref>[http://www.ama-assn.org/ama1/pub/upload/mm/365/farletuzumab.pdf Statement On A Nonproprietary Name Adopted By The Usan Council - Farletuzumab], ''American Medical Association''.</ref> which is being investigated for the treatment of [[ovarian cancer]].<ref>ClinicalTrials.gov: [http://www.clinicaltrials.gov/ct2/show/NCT00738699 Phase II Efficacy and Safety Study of MORAb-003 in Platinum-Resistant or Refractory Relapsed Ovarian Cancer]</ref><ref>ClinicalTrials.gov: [http://www.clinicaltrials.gov/ct2/show/NCT00849667 Phase III Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse]</ref>

This drug was developed by [[Morphotek]], Inc.

It is targeted at [[FR-alpha]] which is overexpressed in some cancers such as ovarian cancer.

== References ==
<references/>

{{Monoclonals for tumors}}

[[Category:Monoclonal antibodies]]


{{monoclonal-antibody-stub}}
{{antineoplastic-drug-stub}}